Discovery and mechanism studies of a novel ATG4B inhibitor Ebselen by drug repurposing and its anti-colorectal cancer effects in mice

Abstract

Highlights 1. High-throughput screening of ATG4B inhibitors based on FDA-approved drug library 2. Ebselen can covalently bind to ATG4B at Cys74 3. Ebselen can promote ATG4B oligomerization at Cys292 and Cys361 4. Ebselen suppresses the growth of colorectal cancer cells and xenograft tumors via ATG4B inhibition

Keywords

• ATG4B inhibitor
• Autophagy
• Colorectal cancer
• FDA-approved drug
• High- throughput screening
• Protein oligomerization